On November 27, 2024, Jonathan Wygant, Vice President and Chief Accounting Officer at Veracyte Inc, executed a sale of 5,032 shares of Veracyte Inc (VCYT, Financial). Following this transaction, the insider now holds 42,313 shares of the company. The details of this transaction can be found in the SEC Filing.
Veracyte Inc is a genomic diagnostics company that focuses on improving patient outcomes by providing diagnostic tests that enable more accurate diagnosis and treatment decisions. The company aims to reduce unnecessary surgeries and other invasive procedures, thereby improving the quality of care for patients.
The insider transaction history for Veracyte Inc indicates that there have been no insider purchases over the past year. In contrast, there have been 19 insider sales during the same period. This trend suggests a pattern of selling among insiders.
On the day of the recent sale by Jonathan Wygant, shares of Veracyte Inc were trading at $42.89 each. This price gives the stock a market cap of $3.329 billion. The GF Value for Veracyte Inc is estimated at $32.23, resulting in a price-to-GF-Value ratio of 1.33. This ratio indicates that the stock is significantly overvalued based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated using the following factors:
- Historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow that the stock has traded at.
- A GuruFocus adjustment factor based on the company’s past returns and growth.
- Future estimates of business performance from Morningstar analysts.
This insider activity and valuation data provide a factual overview of the recent transaction and the current market standing of Veracyte Inc.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
